Bupropion


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Smoking cessation As modified-release preparation: Initial: 150 mg once daily for 6 days, then increase to 150 mg bid. Duration: 7-9 wk. Max: 300/day. Depression Initial: 100 mg bid, up to 100 mg tid after 3 days if needed. Max: 150 mg tid. As a modified-release preparation: 150 mg once daily, increased to 150 mg bid after 3 days, then up to 200 mg bid after several wk if needed. Max: 450 mg as a single dose.
Contraindications
Current or history of seizure disorder, eating disorders (e.g. bulimia or anorexia nervosa); CNS tumour, epilepsy; history of bipolar disorder (when used as an aid in smoking cessation). Abrupt withdrawal of alcohol, benzodiazepines, barbiturates, antiepileptic drugs. Severe hepatic cirrhosis. Concomitant admin or w/in 14 days of MAOIs withdrawal.
Special Precautions
Patient w/ bipolar disorders (in the treatment of depression); recent history of MI or unstable heart disease; other risk factors for seizures (e.g. alcohol abuse, diabetes, history of head trauma). Renal or mild to moderate hepatic impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and lightheadedness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor BP and LFT before and during treatment; monitor wkly if used w/ nicotine products. Monitor for worsening and emergence of suicidal thoughts and behaviours.
Adverse Reactions
Headache, dry mouth, nausea, insomnia, dizziness, pharyngitis, constipation, agitation, anxiety, abdominal pain, tinnitus, tremor, nervousness, somnolence, irritability, vasodilation, photosensitivity, hypertonia, suicidal ideation, emotional lability, hostility, palpitation, myalgia, twitch, sweating, rash, nausea, migraine, insomnia, pharyngitis, urinary frequency or retention, hot flushes, dysphagia, flushing, anorexia, chills, facial eodema, photosensitivity, hypotension, stroke, tachycardia, gastric reflux, gingivitis, increased salivation, jaundice, mouth ulcers, stomatitis, thirst, ecchymosis, leg cramps, decreased libido, depersonalisation, dysphoria, vertigo, phlebitis, pulmonary embolism, colitis, aesophagitis, GI hemorrhage, hepatitis, intestinal perforation, pancreatitis, stomach ulcer, hyperglycaemia, hypoglycaemia, anaemia, muscle weakness, fever, rhabdomyolysis, euphoria, delirium, pneumonia, Stevens-Johnson syndrome, mydriasis, deafness, increased intraocular pressure, abnormal ejaculation, cystitis, vaginitis, and salpingitis.
Drug Interactions
Observe extreme caution w/ concurrent admin of drugs that lower seizure threshold (e.g. other antidepressants, antipsychotics, theophylline, systemic corticosteroids). Increased risk of side effects w/ levodopa or amantadine. Decreased exposure w/ CYP2B6 inducers (e.g. ritonavir, lopinavir, efavirenz). May increase exposure of CYP2D6 substrates (e.g. venlafaxine, fluoxetine, antipsychotics, β-blockers, type 1C antiarrhythmics.
ATC Classification
N06AX12 - bupropion ; Belongs to the class of other antidepressants.
Disclaimer: This information is independently developed by CIMS based on bupropion from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in